Status:
COMPLETED
This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to describe the usage of NOACs in patients with NVAF, in the hospital setting, based on the baseline characteristics at the time of first NOAC initiation.
Eligibility Criteria
Inclusion
- The patient is willing and provides written informed consent to participate in this study
- The patient is at least 18 years of age
- The patient has a diagnosis of non-valvular atrial fibrillation (NVAF)
- The patient is on treatment with NOAC according to its approved local SmPC and has initiated his first NOAC starting from November 2016
Exclusion
- if the current participating patient participate in any clinical trial of a drug or device will be excluded
Key Trial Info
Start Date :
November 29 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2019
Estimated Enrollment :
1008 Patients enrolled
Trial Details
Trial ID
NCT03285373
Start Date
November 29 2017
End Date
January 31 2019
Last Update
February 18 2020
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Clínica Modelo
A Coruña, Spain, 15011
2
Hospital Universatio de Albacete
Albacete, Spain, 2006
3
Hospital Quirónsalud Sur
Alcorcón (Madrid), Spain, 28922
4
Hospital General Universitario de Alicante
Alicante, Spain, 03010